ISU ABXIS to release first antibodytherapeutic
Published: 2007-03-19 06:56:00
Updated: 2007-03-19 06:56:00
ISU ABXIS Inc., a local biotechnology specialized in developing and manufacturing therapeutic antibodies, said it will launch its first antibody therapeutic Clotinab (anti-GP IIb/IIIa mAb), followed by the development of other four therapeutic proteins in the pipeline.
ISU ABXIS's Clotinab, th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
